{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:46:23Z","timestamp":1792525583180,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.intimp.2026.117542","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:52:06Z","timestamp":1792155126000},"page":"117542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ensifentrine inhibits lipopolysaccharide-induced production of cytokines by human lung macrophages: a comparison with roflumilast, and an interaction with adenosine"],"prefix":"10.1016","volume":"190","author":[{"given":"M.","family":"Brollo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Salvator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Glorion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Marquant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roquencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grassin-Delyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117542_bb0005","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100042","article-title":"Cyclic nucleotide phosphodiesterases as drug targets","volume":"77","author":"Kelly","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.intimp.2026.117542_bb0015","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1183\/09031936.95.08071179","article-title":"PDE isoenzymes as targets for anti-asthma drugs","volume":"8","author":"Schudt","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2026.117542_bb0020","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2222.1995.tb01110.x","article-title":"Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages","volume":"25","author":"Tenor","year":"1995","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.intimp.2026.117542_bb0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.bjp.0701124","article-title":"In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor- \u03b1 release by PDE inhibitors","volume":"121","author":"Gantner","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0030","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1476-5381.2011.01667.x","article-title":"Roflumilast inhibits the release of chemokines and TNF-\u03b1 from human lung macrophages stimulated with lipopolysaccharide","volume":"165","author":"Buenestado","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0035","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pupt.2012.01.003","article-title":"Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells","volume":"25","author":"Tannheimer","year":"2012","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.117542_bb0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/jpet.113.210997","article-title":"The in vitro pharmacology of GS-5759, A novel bifunctional phosphodiesterase 4 inhibitor and long acting \u03b22-adrenoceptor agonist","volume":"349","author":"Tannheimer","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2026.117542_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2005.12.056","article-title":"Adenosine in the airways: implications and applications","volume":"533","author":"Spicuzza","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0050","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.tips.2009.07.005","article-title":"Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease","volume":"30","author":"Polosa","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2026.117542_bb0055","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.intimp.2026.117542_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.604944","article-title":"Adenosine at the interphase of hypoxia and inflammation in lung injury","volume":"11","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117542_bb0065","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1006\/jmcc.1996.0113","article-title":"Ischemic preconditioning: bioenergetic and metabolic changes and the role of endogenous adenosine","volume":"28","author":"Headrick","year":"1996","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.intimp.2026.117542_bb0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","article-title":"Adenosine receptors as drug targets \u2014 what are the challenges?","volume":"12","author":"Chen","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.117542_bb0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.intimp.2026.117542_bb0080","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1476-5381.2009.00614.x","article-title":"The role of adenosine receptors in regulating production of tumour necrosis factor-\u03b1 and chemokines by human lung macrophages","volume":"159","author":"Buenestado","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0085","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s00210-025-04558-1","article-title":"A comprehensive systematic review and meta-analysis of ensifentrine in COPD: dose-dependent effects, safety profile, and GRADE-based certainty of evidence","volume":"399","author":"Abou Elezz","year":"2026","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0095","first-page":"CD002309","article-title":"Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease","volume":"5","author":"Janjua","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2026.117542_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105904","article-title":"The effect of doxofylline in asthma and COPD","volume":"164","author":"Cazzola","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.intimp.2026.117542_bb0110","doi-asserted-by":"crossref","first-page":"2004564","DOI":"10.1183\/13993003.04564-2020","article-title":"Methylxanthines in COPD: yes to caffeine, no to theophylline","volume":"57","author":"Kunisaki","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2026.117542_bb0115","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1111\/bph.13210","article-title":"15-lipoxygenases regulate the production of chemokines in human lung macrophages","volume":"172","author":"Abrial","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111557","article-title":"The IL-4\/13-induced production of M2 chemokines by human lung macrophages is enhanced by adenosine and PGE2","volume":"128","author":"Brollo","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0125","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1164\/ajrccm.155.3.9117029","article-title":"Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome","volume":"155","author":"Martin","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2026.117542_bb0130","first-page":"L87","article-title":"Quantitative comparison of C-X-C chemokines produced by endotoxin-stimulated human alveolar macrophages","volume":"275","author":"Goodman","year":"1998","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.intimp.2026.117542_bb0135","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-82-6-784","article-title":"Theophylline-induced seizures in adults: correlation with serum concentrations","volume":"82","author":"Zwillich","year":"1975","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2026.117542_bb0140","first-page":"181","article-title":"Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline","volume":"125","author":"Vozeh","year":"1982","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.intimp.2026.117542_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/j.1875-9114.1983.tb04531.x","article-title":"Theophylline. A \u201cstate of the art\u201d review","volume":"3","author":"Hendeles","year":"1983","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.intimp.2026.117542_bb0150","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/fcp.12626","article-title":"Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long-acting beta-2-agonist","volume":"35","author":"Salvator","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1465-9921-14-134","article-title":"The expression and relaxant effect of bitter taste receptors in human bronchi","volume":"14","author":"Grassin-Delyle","year":"2013","journal-title":"Respir. Res."},{"key":"10.1016\/j.intimp.2026.117542_bb0160","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12931-017-0613-y","article-title":"Human lung and monocyte-derived macrophages differ with regard to the effects of \u03b22-adrenoceptor agonists on cytokine release","volume":"18","author":"Victoni","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.intimp.2026.117542_bb0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pupt.2015.03.007","article-title":"Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3\/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways","volume":"32","author":"Calzetta","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.117542_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105801","article-title":"Indacaterol, glycopyrronium, and mometasone: pharmacological interaction and anti-inflammatory profile in hyperresponsive airways","volume":"172","author":"Rogliani","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.117542_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224137","article-title":"Statistical determination of synergy based on bliss definition of drugs independence","volume":"14","author":"Demidenko","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2026.117542_bb0185","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1124\/jpet.105.099192","volume":"318","author":"Boswell-Smith","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2026.117542_bb0190","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1159\/000545645","article-title":"Anti-inflammatory activity of Ensifentrine: A novel, selective dual inhibitor of phosphodiesterase 3 and phosphodiesterase 4","volume":"104","author":"Rheault","year":"2025","journal-title":"Respiration"},{"key":"10.1016\/j.intimp.2026.117542_bb0200","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/002013240204701105","article-title":"Assessing nebulizer performance","volume":"47","author":"Dolovich","year":"2002","journal-title":"Respir. Care"},{"key":"10.1016\/j.intimp.2026.117542_bb0205","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thx.48.3.220","article-title":"Lung deposition of nebulised pentamidine in children","volume":"48","author":"O'Doherty","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.intimp.2026.117542_bb0210","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/ajrccm\/147.5.1279","article-title":"Lung distribution and pharmacokinetics of aerosolized tobramycin","volume":"147","author":"Le Conte","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.intimp.2026.117542_bb0215","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/bdd.2510140511","article-title":"Relationship between lung tissue and blood plasma concentrations of inhaled budesonide","volume":"14","author":"Van den Bosch","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.intimp.2026.117542_bb0220","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1183\/09031936.97.10071496","article-title":"Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo","volume":"10","author":"Esmailpour","year":"1997","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2026.117542_bb0225","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/ajrccm.165.2.2107025","article-title":"Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs","volume":"165","author":"Goldstein","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2026.117542_bb0230","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00134-008-1126-4","article-title":"Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers","volume":"34","author":"Ferrari","year":"2008","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.intimp.2026.117542_bb0235","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00134-010-1879-4","article-title":"Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa","volume":"36","author":"Lu","year":"2010","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.intimp.2026.117542_bb0240","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/ALN.0000000000002752","article-title":"Lung pharmacokinetics of tobramycin by intravenous and nebulized dosing in a mechanically ventilated healthy ovine model","volume":"131","author":"Dhanani","year":"2019","journal-title":"Anesthesiology"},{"key":"10.1016\/j.intimp.2026.117542_bb0245","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/ALN.0000000000003171","article-title":"Nebulization of vancomycin provides higher lung tissue concentrations than intravenous administration in ventilated female piglets with healthy lungs","volume":"132","author":"de M. Morais","year":"2020","journal-title":"Anesthesiology"},{"key":"10.1016\/j.intimp.2026.117542_bb0250","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2026.117542_bb0255","first-page":"26","article-title":"Dose-proportional Intraindividual single- and repeated-dose pharmacokinetics of Roflumilast, an Oral, once-daily phosphodiesterase 4 inhibitor","volume":"47","author":"Bethke","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.intimp.2026.117542_bb0260","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.117542_bb0265","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CPP49051","article-title":"High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast","volume":"49","author":"Bethke","year":"2011","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.117542_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115814","article-title":"Anti-oxidative and anti-inflammatory effects of the phosphodiesterase 3\/4 inhibitor ensifentrine","volume":"168","author":"Lea","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0275","first-page":"1225","article-title":"The pulmonary disposition of theophylline and its influence on human alveolar macrophage bactericidal function","volume":"134","author":"O'Neill","year":"1986","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.intimp.2026.117542_bb0280","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1440-1681.1978.tb00707.x","article-title":"Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline","volume":"5","author":"Polson","year":"1978","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.intimp.2026.117542_bb0285","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1165\/ajrcmb.10.5.8179921","article-title":"Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition","volume":"10","author":"Dent","year":"1994","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.intimp.2026.117542_bb0290","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2016_71","article-title":"Xanthines and phosphodiesterase inhibitors","volume":"237","author":"Spina","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117542_bb0295","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2172-13-57","article-title":"Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogates","volume":"13","author":"Groot-Kormelink","year":"2012","journal-title":"BMC Immunol."},{"key":"10.1016\/j.intimp.2026.117542_bb0300","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1189\/jlb.0206124","article-title":"cDNA microarray analysis reveals fundamental differences in the expression profiles of primary human monocytes, monocyte-derived macrophages, and alveolar macrophages","volume":"81","author":"Li","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2026.117542_bb0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000494463","article-title":"The role of toll-like receptors in the production of cytokines by human lung macrophages","volume":"12","author":"Grassin-Delyle","year":"2020","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.intimp.2026.117542_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074640","article-title":"Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-\u03b1 and chemokine production by human lung parenchyma","volume":"8","author":"Buenestado","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2026.117542_bb0315","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1155\/S0962935192000620","article-title":"Differential regulation of TNF-alpha and IL-1beta production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors","volume":"1","author":"Molnar-Kimber","year":"1992","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2026.117542_bb0320","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0954-6111(99)90077-X","article-title":"The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications","volume":"93","author":"Poulakis","year":"1999","journal-title":"Respir. Med."},{"key":"10.1016\/j.intimp.2026.117542_bb0325","doi-asserted-by":"crossref","first-page":"21978","DOI":"10.1073\/pnas.0911684106","article-title":"Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages","volume":"106","author":"Hertz","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.117542_bb0330","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1183\/09031936.00158008","article-title":"Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages","volume":"36","author":"Donnelly","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2026.117542_bb0335","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70046","article-title":"Differences in the inflammatory response and corticoid responsiveness of human lung macrophages and parenchymal explants exposed to cigarette smoke extracts","volume":"136","author":"Brollo","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.intimp.2026.117542_bb0340","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-11-124","article-title":"Differential cell reaction upon toll-like receptor 4 and 9 activation in human alveolar and lung interstitial macrophages","volume":"11","author":"Hoppst\u00e4dter","year":"2010","journal-title":"Respir. Res."},{"key":"10.1016\/j.intimp.2026.117542_bb0345","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5160794","article-title":"Lung interstitial macrophages: past, present, and future","volume":"2018","author":"Schyns","year":"2018","journal-title":"J. Immunol. Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926013901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926013901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:36:50Z","timestamp":1792525010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926013901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":65,"alternative-id":["S1567576926013901"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117542","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ensifentrine inhibits lipopolysaccharide-induced production of cytokines by human lung macrophages: a comparison with roflumilast, and an interaction with adenosine","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117542"}}